Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Legend Biotech Corp(LEGN)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LEGN
10/08/2026: LEGN (1-star) is currently NOT-A-BUY. Pass it for now.
Legend Biotech is a clinical-stage biopharmaceutical firm specialized in developing CAR-T cell therapies for oncology. The company has successfully reached a major milestone with the commercial launch of its flagship product, CARVYKTI, in partnership with Johnson & Johnson. Its main investment story centers on the potential for market expansion in earlier lines of cancer treatment and the development of its broader pipeline. Risks include heavy reliance on a single commercial product, high operational complexity, and intense competitive pressures in the biotech sector. The stock is best suited for growth-oriented investors who can tolerate significant volatility associated with clinical-stage biotech development and evolving commercial execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | The company's focus on innovative oncology therapies and its transition to commercial stage align with growth-oriented investment strategies. |
| Momentum investor | Mixed fit | Momentum appeal is conditional on positive clinical data readouts and consistent commercial execution reports. |
| Value investor | Weak fit | The company is not currently valued based on traditional earnings multiples due to its growth-stage profile. |
| Dividend investor | Weak fit | Legend Biotech does not pay dividends and reinvests all capital into research and infrastructure. |
| Low-risk investor | Weak fit | The company faces inherent biotech volatility, clinical trial risks, and regulatory uncertainties. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech stocks often experience significant price swings based on clinical data updates and regulatory news. |
| Valuation risk | Medium / high | Valuations are heavily dependent on future projections for pipeline success and market penetration. |
| Competition risk (CAR-T therapy competition) | High | Multiple large-cap pharmaceutical companies are aggressively competing for market share in the myeloma space. |
| Business quality | Medium | While the technology is advanced, the business remains dependent on successful commercial scaling and partner collaboration. |
| Dividend income | Low / none | Investors should not expect income returns from this growth-stage asset. |
| Execution risk | Medium / high | Successfully manufacturing and delivering personalized cell therapies globally is a significant operational challenge. |
Price Behavior
Rolling Over
The price momentum is slowing down and beginning to turn downward.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 5.5% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  4.0 | Stock Returns Performance  2.0 |
| Profits based on simulation | Last Close 10/08/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 3.72B USD | Price to earnings Ratio - | 1Y Target Price 46.5 |
Price to earnings Ratio - | 1Y Target Price 46.5 | ||
Volume (30-day avg) 2.1M shares | Beta 0.57 | 52 Weeks Range 16.24 - 37.50 | Updated Date 10/08/2026 |
52 Weeks Range 16.24 - 37.50 | Updated Date 10/08/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.52 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Product Revenue | Direct sales of CARVYKTI in the US and international markets. | This is the core revenue generated from patients actually using the therapy. |
| Collaboration Revenue | Milestone payments and profit-sharing arrangements with Janssen/Johnson & Johnson. | This reflects the value of the partnership in scaling the therapy globally. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Valuation
Trailing PE - | Forward PE 27.55 | Enterprise Value 2.90B | Price to Sales(TTM) 2.92 |
Enterprise Value 2.90B | Price to Sales(TTM) 2.92 | ||
Enterprise Value to Revenue 2.28 | Enterprise Value to EBITDA 252.34 | Shares Outstanding 194.49M | Shares Floating 193.54M |
Shares Outstanding 194.49M | Shares Floating 193.54M | ||
Percent Insiders 1.86 | Percent Institutions 56.86 |
Upturn AI Summary
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
About Legend Biotech Corp
Exchange NASDAQ | Headquarters Somerset, NJ, United States | ||
IPO Launch date 2020-06-05 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 3200 | Website https://legendbiotech.com |
Full time employees 3200 | Website https://legendbiotech.com | ||
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.